SCORED Trial: Sotagliflozin Showed Robust MACE Benefit
Trial results for the 'twincretin' in patients with diabetes, CKD, and high CVD risk showed robust benefits across MACE outcomes, distinguishing sotagliflozin from the SGLT2 inhibitors.
Medscape Medical News
source https://www.medscape.com/viewarticle/971487?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/971487?src=rss
Comments
Post a Comment